179 related articles for article (PubMed ID: 22203591)
21. In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
Pillar CM; Torres MK; Brown NP; Shah D; Sahm DF
Antimicrob Agents Chemother; 2008 Dec; 52(12):4388-99. PubMed ID: 18779357
[TBL] [Abstract][Full Text] [Related]
22. [A comparison of susceptibility of Pseudomonas aeruginosa clinical isolates to carbapenem antibiotics in our hospital].
Kakeya H; Yamada K; Nakaie K; Takizawa E; Okada Y; Fujita A; Nakamura Y; Abe J; Hirose A; Kaneko Y; Hino M
Jpn J Antibiot; 2014 Aug; 67(4):241-8. PubMed ID: 25420320
[TBL] [Abstract][Full Text] [Related]
23. Characterization of clinical isolates of Pseudomonas aeruginosa heterogeneously resistant to carbapenems.
Pournaras S; Ikonomidis A; Markogiannakis A; Spanakis N; Maniatis AN; Tsakris A
J Med Microbiol; 2007 Jan; 56(Pt 1):66-70. PubMed ID: 17172519
[TBL] [Abstract][Full Text] [Related]
24. Bacterial strain-independent AUC/MIC and strain-specific dose-response relationships reflecting comparative fluoroquinolone anti-pseudomonal pharmacodynamics in an in vitro dynamic model.
Lubenko IY; Vostrov SN; Portnoy YA; Zinner SH; Firsov AA
Int J Antimicrob Agents; 2002 Jul; 20(1):44-9. PubMed ID: 12127710
[TBL] [Abstract][Full Text] [Related]
25. Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases.
Moczygemba LR; Frei CR; Burgess DS
Clin Ther; 2004 Nov; 26(11):1800-7. PubMed ID: 15639692
[TBL] [Abstract][Full Text] [Related]
26. Pseudomonas aeruginosa is not just in the intensive care unit any more: implications for empirical therapy.
Eagye KJ; Banevicius MA; Nicolau DP
Crit Care Med; 2012 Apr; 40(4):1329-32. PubMed ID: 22425824
[TBL] [Abstract][Full Text] [Related]
27. Assessing the pharmacodynamic profile of intravenous antibiotics against prevalent Gram-negative organisms collected in Colombia.
Villegas MV; Briceno DF; Ruiz SJ; Furtado GH; Nicolau DP
Braz J Infect Dis; 2011; 15(5):413-9. PubMed ID: 22230846
[TBL] [Abstract][Full Text] [Related]
28. Bacterial antibiotic resistance studies using in vitro dynamic models: Population analysis vs. susceptibility testing as endpoints of mutant enrichment.
Firsov AA; Strukova EN; Portnoy YA; Shlykova DS; Zinner SH
Int J Antimicrob Agents; 2015 Sep; 46(3):313-8. PubMed ID: 26297633
[TBL] [Abstract][Full Text] [Related]
29. MIC score, a new tool to compare bacterial susceptibility to antibiotics application to the comparison of susceptibility to different penems of clinical strains of Pseudomonas aeruginosa.
Bretonnière C; Maitte A; Caillon J; Potel G; Boutoille D; Jacqueline C; Guitton C
J Antibiot (Tokyo); 2016 Nov; 69(11):806-810. PubMed ID: 27025352
[TBL] [Abstract][Full Text] [Related]
30. Comparative review of the carbapenems.
Zhanel GG; Wiebe R; Dilay L; Thomson K; Rubinstein E; Hoban DJ; Noreddin AM; Karlowsky JA
Drugs; 2007; 67(7):1027-52. PubMed ID: 17488146
[TBL] [Abstract][Full Text] [Related]
31. Antimicrobial activity of doripenem and other carbapenems against gram-negative pathogens from Korea.
Lee H; Ko KS; Song JH; Peck KR
Microb Drug Resist; 2011 Mar; 17(1):37-45. PubMed ID: 20950191
[TBL] [Abstract][Full Text] [Related]
32. Longitudinal survey of carbapenem resistance and resistance mechanisms in Enterobacteriaceae and non-fermenters from the USA in 2007-09.
Davies TA; Marie Queenan A; Morrow BJ; Shang W; Amsler K; He W; Lynch AS; Pillar C; Flamm RK
J Antimicrob Chemother; 2011 Oct; 66(10):2298-307. PubMed ID: 21775338
[TBL] [Abstract][Full Text] [Related]
33. Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model.
Madaras-Kelly KJ; Ostergaard BE; Hovde LB; Rotschafer JC
Antimicrob Agents Chemother; 1996 Mar; 40(3):627-32. PubMed ID: 8851583
[TBL] [Abstract][Full Text] [Related]
34. Activity of ACHN-490 tested alone and in combination with other agents against Pseudomonas aeruginosa.
Pankuch GA; Lin G; Kubo A; Armstrong ES; Appelbaum PC; Kosowska-Shick K
Antimicrob Agents Chemother; 2011 May; 55(5):2463-5. PubMed ID: 21282445
[TBL] [Abstract][Full Text] [Related]
35. In vivo pharmacokinetics/pharmacodynamics of colistin and imipenem in Pseudomonas aeruginosa biofilm infection.
Hengzhuang W; Wu H; Ciofu O; Song Z; Høiby N
Antimicrob Agents Chemother; 2012 May; 56(5):2683-90. PubMed ID: 22354300
[TBL] [Abstract][Full Text] [Related]
36. Synergistic killing of multidrug-resistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in vitro pharmacokinetic/pharmacodynamic model.
Bergen PJ; Tsuji BT; Bulitta JB; Forrest A; Jacob J; Sidjabat HE; Paterson DL; Nation RL; Li J
Antimicrob Agents Chemother; 2011 Dec; 55(12):5685-95. PubMed ID: 21911563
[TBL] [Abstract][Full Text] [Related]
37. Successful treatment with doripenem and tobramycin of ventriculitis due to imipenem- and meropenem-resistant Pseudomonas aeruginosa.
Gelfand MS; Cleveland KO; Mazumder SA
J Antimicrob Chemother; 2009 Jun; 63(6):1297-9. PubMed ID: 19369268
[No Abstract] [Full Text] [Related]
38. Activities of doripenem against nosocomial bacteremic drug-resistant Gram-negative bacteria in a medical center in Taiwan.
Dong SX; Wang JT; Chang SC
J Microbiol Immunol Infect; 2012 Dec; 45(6):459-64. PubMed ID: 23102796
[TBL] [Abstract][Full Text] [Related]
39. In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.
Crandon JL; Bulik CC; Nicolau DP
Antimicrob Agents Chemother; 2009 Oct; 53(10):4352-6. PubMed ID: 19770286
[TBL] [Abstract][Full Text] [Related]
40. The laboratory diagnosis of Pseudomonas aeruginosa that produce metallo-β-lactamases in a Dutch tertiary care centre.
van der Bij AK; Mol M; van Westreenen M; Goessens WH; Pitout JD
Scand J Infect Dis; 2011 Aug; 43(8):596-602. PubMed ID: 21506891
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
